Nicola Tecce

Dr. Nicola Tecce

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 June 2023 in Nutrients
Verified
Journal Article
Open access
PDF file
SNsara novi
sara novi
Vincenzo VestutoVincenzo Vestuto
Vincenzo Vestuto
Pietro CampigliaPietro Campiglia
Pietro Campiglia
NTNicola Tecce
Nicola Tecce
Alessia BertaminoAlessia Bertamino
Alessia Bertamino
Mario Felice TecceMario Felice Tecce
Mario Felice Tecce
Alcoholic liver disease (ALD) and non-alcoholic fatty liver disease (NAFLD) are the most common causes of chronic liver disease and are increasingly emerging as a global health problem. Such disorders can lead to liver damage, resulting in the release of pro-inflammatory cytokines and the activation of infiltrating immune cells. These are some of the common features of ALD progression in ASH (alcoholic steatohepatitis) and NAFLD to NASH (non-alcoholic steatohepatitis). Hepatic steatosis, followed by fibrosis, lead to a continuous progression accompanied by angiogenesis. This process creates hypoxia, which activates vascular factors, initiating pathological angiogenesis and further fibrosis. This forms a vicious cycle of ongoing damage and progression. This condition further exacerbates liver injury and may contribute to the development of comorbidities, such as metabolic syndrome as well as hepatocellular carcinoma. Increasing evidence suggests that anti-angiogenic therapy may have beneficial effects on these hepatic disorders and their exacerbation. Therefore, there is a great interest to deepen the knowledge of the molecular mechanisms of natural anti-angiogenic products that could both prevent and control liver diseases. In this review, we focus on the role of major natural anti-angiogenic compounds against steatohepatitis and determine their potential therapeutic benefits in the treatment of liver inflammation caused by an imbalanced diet.

31 January 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
NTNicola Tecce
Nicola Tecce
Gilda CennamoGilda Cennamo
Gilda Cennamo
MRMichele Rinaldi
Michele Rinaldi
CCCiro Costagliola
Ciro Costagliola
Annamaria ColaoAnnamaria Colao
Annamaria Colao
This review addresses the complexities of type 1 diabetes (T1D) and its associated complications, with a particular focus on diabetic retinopathy (DR). This review outlines the progression from non-proliferative to proliferative diabetic retinopathy and diabetic macular edema, highlighting the role of dysglycemia in the pathogenesis of these conditions. A significant portion of this review is devoted to technological advances in diabetes management, particularly the use of hybrid closed-loop systems (HCLSs) and to the potential of open-source HCLSs, which could be easily adapted to different patients’ needs using big data analytics and machine learning. Personalized HCLS algorithms that integrate factors such as patient lifestyle, dietary habits, and hormonal variations are highlighted as critical to reducing the incidence of diabetes-related complications and improving patient outcomes.

29 March 2024 in Healthcare
Verified
Journal Article
Open access
PDF file
NTNicola Tecce
Nicola Tecce
Giorgio de AlteriisGiorgio de Alteriis
Giorgio de Alteriis
GAGiulia de Alteriis
Giulia de Alteriis
LVLudovica Verde
Ludovica Verde
Mario Felice TecceMario Felice Tecce
Mario Felice Tecce
Giovanna MuscogiuriGiovanna Muscogiuri
Giovanna Muscogiuri
Heart failure (HF) management in type 1 diabetes (T1D) is particularly challenging due to its increased prevalence and the associated risks of hospitalization and mortality, driven by diabetic cardiomyopathy. Sodium–glucose cotransporter-2 inhibitors (SGLT2-is) offer a promising avenue for treating HF, specifically the preserved ejection fraction variant most common in T1D, but their utility is hampered by the risk of euglycemic diabetic ketoacidosis (DKA). This review investigates the potential of SGLT2-is in T1D HF management alongside emergent Continuous Ketone Monitoring (CKM) technology as a means to mitigate DKA risk through a comprehensive analysis of clinical trials, observational studies, and reviews. The evidence suggests that SGLT2-is significantly reduce HF hospitalization and enhance cardiovascular outcomes. However, their application in T1D patients remains limited due to DKA concerns. CKM technology emerges as a crucial tool in this context, offering real-time monitoring of ketone levels, which enables the safe incorporation of SGLT2-is into treatment regimes by allowing for early detection and intervention in the development of ketosis. The synergy between SGLT2-is and CKM has the potential to revolutionize HF treatment in T1D, promising improved patient safety, quality of life, and reduced HF-related morbidity and mortality. Future research should aim to employ clinical trials directly assessing this integrated approach, potentially guiding new management protocols for HF in T1D.

Verified
Journal Article
Open access
PDF file
Giuseppe Della PepaGiuseppe Della Pepa
Giuseppe Della Pepa
GLGianluca Lombardi
Gianluca Lombardi
SGSalvatore Gianfrancesco
Salvatore Gianfrancesco
RPRoberto Piccolo
Roberto Piccolo
GCGiovanni Chirico
Giovanni Chirico
GSGennaro Saldalamacchia
Gennaro Saldalamacchia
Background: The use of dressings is an essential component of the standard of care for diabetic foot ulcers (DFUs); however, despite the wide variety of dressings available, there is a lack of evidence from head-to-head randomized controlled trials. We evaluated the efficacy and safety of Triticum vulgare extract and polyhexanide (Fitostimoline® hydrogel/Fitostimoline® Plus gauze) versus saline gauze dressings in patients with DFUs. Methods: This study involved a monocentric, two-arm, open-label, controlled trial in patients with DFUs (Grades I or II, Stage A or C, based on the Texas classification) randomized to 12 weeks of dressing with Fitostimoline® hydrogel/Fitostimoline® Plus gauze or saline gauze. The number of patients with complete healing, the reduction in DFU size, and the presence of local signs and symptoms of the wound and perilesional skin were evaluated every two weeks and at the end of treatment. Results: A total of 40 adult patients were recruited (20 patients in each treatment group). The proportion of patients with complete healing was similar between the two groups (61% vs. 74%, p = 0.495, Fitostimoline® hydrogel/Fitostimoline® Plus gauze vs. saline gauze, respectively), without significant differences, as well as the reduction in DFU size. A significant improvement in local signs and symptoms of the wound and signs of perilesional skin in the Fitostimoline® hydrogel/Fitostimoline® Plus gauze compared with the saline gauze group was observed. Conclusions: In a clinical setting, the use of Fitostimoline® hydrogel/Fitostimoline® Plus gauze dressing in patients with DFUs significantly improves signs and symptoms of the wound and signs of perilesional skin compared with saline gauze dressing with a similar efficacy in terms of wound healing.

21 May 2025 in Diabetes Care
Verified
Journal Article
Closed access
NTNicola Tecce
Nicola Tecce
CVClaudia Vetrani
Claudia Vetrani
APAnna Lisa Pelosi
Anna Lisa Pelosi
MAMaddalena Alfiore
Maddalena Alfiore
DMDavide Mayol
Davide Mayol
ACAnnamaria Colao
Annamaria Colao

18 July 2022 in Diabetes Research and Clinical Practice
Verified
Journal Article
Closed access
PDF file
NTNicola Tecce
Nicola Tecce
MMMaria Masulli
Maria Masulli
LPLuisa Palmisano
Luisa Palmisano
SGSalvatore Gianfrancesco
Salvatore Gianfrancesco
RPRoberto Piccolo
Roberto Piccolo
BCB. Capaldo
B. Capaldo